IGF1 and non-small cell lung carcinoma: IRS-1 knockdown via siRNA indicating that IRS-1 and ATM expression levels are downregulated by IGF-1 that could contribute to promoting cisplatin resistance in NSCLC cells and blocking the activation of DSBs repair and checkpoint pathways as well as cisplatin-induced γH2AX formation.